Earlier today Eli Lilly was granted FDA breakthrough status for its Alzheimer’s drug. 

Shares of the stock soared by 7.3% off the news. And it also caused a “sympathy effect” 

In other words, other companies working on Alzheimer’s treatments also saw a spike in their stock price. 

One of them was mentioned to you just a few days ago via our Master Watchlist. 

Shares of ACIU closed at $8.37. A stock will continue to monitor as it approaches its catalyst date. 

However, we’d like to bring to your attention another catalyst stock in the Alzheimer’s space…one that is rarely mentioned…and is trading around $1 per share. 

AIkido Pharma Could Be In Play

Recent Catalysts

Upcoming Catalysts

In early January, Aikido executed a licensing agreement for psilocybin as a cancer application. Using psychedelics to treat cancer is new and exciting in the world of medicine. We’ll know soon enough how policy makers feel about it.

Psychedelic legislation passed the California Senate earlier this month.

There are still more hurdles to cross…and legalization maybe a few months away if all works out as planned. 

Nonetheless, AIKI might be worth playing as a long…leading up to the catalyst.

Based on the chart, it has shown some solid support at $0.80.  Anywhere near that level would seem like a prudent entry—with upside potential at around $1.50.

The firm’s market cap is under $100M. Which means it has the potential to react violently to any news (good or bad). 

Either way, this is one company you should have on your psychedelic watchlist along with CMPS and MNMD.